Incidence of hematological toxicity with use of immunotherapy and chemotherapy in advanced non-small cell lung cancer  

作　　者：Wenhai Fu Yu Jiang Wenjun Ye Ran Zhong Shan Xiong Jianfu Li Caichen Li Jianxing He Wenhua Liang 

机构地区：[1]Department of Thoracic Surgery and Oncology,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510120,China [2]State Key Laboratory of Respiratory Disease,Guangzhou,Guangdong 510120,China [3]National Clinical Research Center for Respiratory Disease,Guangzhou,Guangdong 510120,China [4]Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong 510120,China

出　　处：《Chinese Medical Journal》2025年第2期249-251,共3页中华医学杂志(英文版)

基　　金：funded by the China National Science Foundation(Nos.82022048 and 82373121);the Science and Technology Planning Project of Guangzhou(No.202206080013);the National Key Research&Development Programme(No.2022YFC2505100).

摘　　要：To the Editor:Immunotherapy has overtaken chemotherapy(Chemo)as the frontline mode of treatment for advanced non-small cell lung cancer(NSCLC).The efficacy of immunotherapies such as immune checkpoint inhibitors(ICIs)can be further increased by combining them with Chemo and/or anti-angiogenic therapy.However,these combination treatments are associated with more adverse events,which need to be carefully managed.Although previous meta-analyses have shown that ICI use increased gastrointestinal and skin toxicities,the association between ICIs and hematological toxicity has not been adequately assessed.A study by Kramer et al[1]found that 0.6%of the 7626 ICI-treated patients experienced hematological adverse events;however,only 16%of this group of patients received ICIs+Chemo.Thus,the risks associated with combining ICIs and Chemo may not be fully appreciated.The present study reviewed data from phase III trials of ICIs used in combination with Chemo and/or anti-angiogenic agents to evaluate the hematological toxicity in advanced NSCLC.

关 键 词：IMMUNOTHERAPY immune checkpoint inhibitors icis can advanced non small cell lung cancer anti angiogenic therapy gastrointestinal skin toxiciti hematological toxicity immune checkpoint inhibitors 

分 类 号：R734.2[医药卫生—肿瘤]